Phase II Trial of Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive, Extensive-Stage Small Cell Lung Cancer.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Imatinib (Primary) ; Cisplatin; Irinotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 15 Nov 2010 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
- 15 Nov 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 19 Jul 2006 New trial record.